Open access
Sep 2026
CDKPredict: a clinicogenomic model for risk-adapted therapeutic intervention in breast cancer
Abstract Wide variation in outcomes is observed for patients with hormone-receptor-positive metastatic breast cancer (MBC) receiving first-line CDK4/6 inhibitors plus endocrine therapy (CDK4/6i+ET). Although front-line escalation strategies are beginning to enter clinical practice, assigning patients to intensified or...
Luca Boscolo Bielo, F. Sánchez-Vega, Subhiksha Nandakumar et al.
· Research Square · 0 citations